SecBot SecBot

CCCC

C4 Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001662579 Biotech & Drug Discovery
$2.65 −0.11 (−3.99%)
Nov 16 4:00 PM ET · prev $2.76
Market cap
$363.7M
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$10.50
+296% · range $6.00–30.00
1 year
+6.0%
from $2.50 · Nov 17
30 days
−8.3%
from $2.89
52-week range
$1.71–4.67
−43% from high · low Feb 5
Avg volume 20D
3.06M
shares / day
Short interest
46.58M
≈35.5% of shares · +9.0%
Days to cover
15.1
at average volume
Insider net
−$122.5K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 0 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 2/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $122.5K.

  • InstitutionsBULLISH

    Q3 2026: 28 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.268 → −$0.198 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +9.0% to 46.58M shares. 15.1 days to cover, ≈35.5% of shares.

  • TrendRANGE

    15% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Candriam S.C.A.ADD2,760,346$9.2M
Qube Research & Technologies LtdDOUBLED2,397,086$8.0M
CONGRESS ASSET MANAGEMENT COADD1,256,692$4.2M
FMR LLCADD1,175,723$3.9M
VANGUARD PORTFOLIO MANAGEMENT LLCADD1,094,194$3.6M
MARSHALL WACE, LLPDOUBLED855,805$2.8M
PANAGORA ASSET MANAGEMENT INCDOUBLED690,687$2.3M
Connor, Clark & Lunn Investment Management Ltd.ADD546,352$1.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy4Buy10Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +296%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 28, 2026Lake Street
INITIATE
INITIATEBuy
Oct 9, 2026JP Morgan
INITIATE
INITIATEOverweight
Jun 1, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$122.5K
sold · 1 insider
DateInsiderTypeValue
Nov 12, 2026
Adams Kendra
Chief Financial Officer
Nov 12, 2026
SELL$122.5K
Oct 1, 2026
Anderson Kenneth Carl
Director
Oct 1, 2026
AWARD$11.5K
Oct 1, 2026
GROGAN DONNA ROY
Director
Oct 1, 2026
AWARD$14.5K
Sep 18, 2026
Adams Kendra
Chief Financial Officer
Sep 18, 2026
EXERCISE6,250 sh
Sep 18, 2026
Adams Kendra
Chief Financial Officer
Sep 18, 2026
TAX W/H$9.4K
Jul 10, 2026
REYNO LEONARD
Chief Medical Officer
Jul 10, 2026
EXERCISE15,325 sh
Jul 10, 2026
REYNO LEONARD
Chief Medical Officer
Jul 10, 2026
TAX W/H$30.0K
Jul 1, 2026
Anderson Kenneth Carl
Director
Jul 1, 2026
AWARD$11.5K

Earnings setup

Estimates
−$0.20
EPS estimate, this quarter
+26%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.20-$0.25–-$0.15+27.3%$5.9M
Next Q-$0.26-$0.34–-$0.19+11.9%$5.3M
Current FY-$0.74-$0.80–-$0.69+16.4%$26.9M
Next FY-$0.87-$1.11–-$0.68+13.1%$23.5M

Short side

FINRA· Oct 30, 2026
46,580,600
shares short
+9.0%
vs prior settlement
15.1
days to cover
≈35.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Kendra Adams, an officer of C4 Therapeutics, filed a Form 144 notice of intent to sell 45,173 shares of common stock…
144 · Impact 2/10
Nov 12, 2026 Insider
Adams Kendra sold 45,173 shares
Chief Financial Officer @ $2.71 ($122.5K)
Nov 6, 2026 SEC
Five institutional investors added to C4 Therapeutics positions in Q3 2026, with Candriam S.c.a. and Barclays making…
INST-CLUSTER · Impact 2/10
Nov 5, 2026 Earnings
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data
Oct 1, 2026 Insider
Anderson Kenneth Carl was granted 3,662 shares
Director @ $3.14 ($11.5K)
Oct 1, 2026 Insider
GROGAN DONNA ROY was granted 4,618 shares
Director @ $3.14 ($14.5K)
Sep 30, 2026 Inst.
Candriam S.C.A. · ADD
2,760,346 shares ($9.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 5, 2026
Earnings
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027
Nov 4, 2026
Earnings date
CCCC Q3 2026 Earnings Scheduled · 2026-11-04
Nov 3, 2026
Press release
C4 Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated…
Nov 2, 2026
Press release
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated…
Oct 29, 2026
Press release
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage DEL Technology Integrating C4T’s Cereblon…

SecBot reports

15 filings · 4 press releases · 4 bullish · 0 bearish · 1 mixed · 10 neutral
All CCCC filing & press-release reports (19)